TY - JOUR
T1 - Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
AU - Carlini, Paolo
AU - Ferretti, Gianluigi
AU - Di Cosimo, Serena
AU - Colella, Elvira
AU - Tonachella, Riccardo
AU - Romiti, Adriana
AU - Tomao, Silverio
AU - Frassoldati, Antonio
AU - Papaldo, Paola
AU - Fabi, Alessandra
AU - Ruggeri, Enzo Maria
AU - Cognetti, Francesco
PY - 2003/7
Y1 - 2003/7
N2 - To explore the different sequence interactions between reversible non-steroidal (anastrozole, ANZ and letrozole, LTZ) and non-reversible steroidal aromatase inhibitors (formestane, FOR and exemestane, EXE), we evaluated the clinical benefit (CB) in postmenopausal breast cancer patients, who had previously received anastrozole and subsequently formestane. In 19 out of 21 patients (90.5%), a clinical benefit response was achieved by anastrozole, with a median duration of 12 months. Out of the 21 women progressing on anastrozole, 12 achieved stable disease (SD)≥6 months by formestane only. The overall clinical benefit was 66.5%. The median duration of clinical benefit was 11 months with a time to progression of 6.5 months. The median duration of clinical benefit in our series is similar to that reported in two phase II trials with the sequence aminogluthetimide→formestane and aminogluthetimide→exemestane as third-line hormonal therapy, suggesting a non-cross-resistance between the two classes of inhibitors.
AB - To explore the different sequence interactions between reversible non-steroidal (anastrozole, ANZ and letrozole, LTZ) and non-reversible steroidal aromatase inhibitors (formestane, FOR and exemestane, EXE), we evaluated the clinical benefit (CB) in postmenopausal breast cancer patients, who had previously received anastrozole and subsequently formestane. In 19 out of 21 patients (90.5%), a clinical benefit response was achieved by anastrozole, with a median duration of 12 months. Out of the 21 women progressing on anastrozole, 12 achieved stable disease (SD)≥6 months by formestane only. The overall clinical benefit was 66.5%. The median duration of clinical benefit was 11 months with a time to progression of 6.5 months. The median duration of clinical benefit in our series is similar to that reported in two phase II trials with the sequence aminogluthetimide→formestane and aminogluthetimide→exemestane as third-line hormonal therapy, suggesting a non-cross-resistance between the two classes of inhibitors.
KW - Anastrozole
KW - Formestane
KW - Postmenopausal metastatic breast cancer (PMBC)
UR - http://www.scopus.com/inward/record.url?scp=0042928054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042928054&partnerID=8YFLogxK
U2 - 10.1016/S0960-0760(03)00249-8
DO - 10.1016/S0960-0760(03)00249-8
M3 - Article
C2 - 12943750
AN - SCOPUS:0042928054
VL - 86
SP - 107
EP - 109
JO - Journal of Steroid Biochemistry and Molecular Biology
JF - Journal of Steroid Biochemistry and Molecular Biology
SN - 0960-0760
IS - 1
ER -